CR
Caribou Biosciences, Inc.
CRBU · NASDAQ
$1.30 -0.76% (-$0.01)
1M -20.73%
Market Cap $128.9M
P/E Ratio -
Div. Yield -
ROE 89.11%
Bulios Fair Price
$1.35
3.8% upside
Current Price
$1.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRBU is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/B 1.31x
P/S 12.85x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 25.95%
Rev. growth 6.95%
FCF growth N/A
Profitability
0 /100
Weak Net margin 1,030.42%
Op. margin 1,090.90%
FCF margin 954.18%
Quality
1 /100
Poor ROE 89.11%
ROA 72.42%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.49x
Debt/Equity 0.27x
Net debt/EBITDA N/A
Stability
29 /100
Unstable Rev. volatility 111.09%
EPS volatility 17.99%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRBU
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Rachel E. Haurwitz
Employees
97
Headquarters
Berkeley
Upcoming events
11 NOV
Earnings
Upcoming earnings report